Evidence map›Paper›PMID 39280006›Full record

ArticleFrontiers in endocrinology2024

Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes.

Katsuhito Mori, Tsutomu Inoue, Yuri Machiba, Hideki Uedono, Shinya Nakatani, Masahiro Ishikawa, Satsuki Taniuchi, Yutaka Katayama, Akira Yamamoto, Naoki Kobayashi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Katsuhito MoriDepartment of Nephrology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Tsutomu InoueDepartment of Nephrology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Yuri MachibaDepartment of Metabolism, Endocrinology and Molecular Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Hideki UedonoDepartment of Metabolism, Endocrinology and Molecular Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Shinya NakataniDepartment of Metabolism, Endocrinology and Molecular Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Masahiro IshikawaDepartment of Nephrology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Satsuki TaniuchiDepartment of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yutaka KatayamaDepartment of Radiology, Osaka Metropolitan University Hospital, Osaka, Japan.
Akira YamamotoDepartment of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Naoki KobayashiSchool of Clinical Engineering, Faculty of Health and Medical Care, Saitama Medical University, Saitama, Japan.
Eito KozawaDepartment of Radiology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Taro ShimonoDepartment of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Yukio MikiDepartment of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Hirokazu OkadaDepartment of Nephrology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Masanori EmotoDepartment of Nephrology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent clinical studies suggest protective effects of SGLT2 inhibitors on kidney disease outcome. Chronic hypoxia has a critical role in kidney disease development, thus we speculated that canagliflozin, an SGLT2 inhibitor, can improve kidney oxygenation. Methods: A single-arm study was conducted to investigate the effects of canagliflozin on T2* value, which reflects oxygenation level, in patients with type 2 diabetes (T2D) using repeated blood oxygenation level-dependent MRI (BOLD MRI) examinations. Changes in cortical T2* from before (Day 0) to after single-dose treatment (Day 1) and after five consecutive treatments (Day 5) were evaluated using 12-layer concentric objects (TLCO) and region of interest (ROI) methods. Results: In the full analysis set (n=14 patients), the TLCO method showed no change of T2* with canagliflozin treatment, whereas the ROI method found that cortical T2* was significantly increased on Day 1 but not on Day 5. Sensitivity analysis using TLCO in 13 well-measured patients showed that canagliflozin significantly increased T2* on Day 1 with no change on Day 5, whereas a significant improvement in cortical T2* following canagliflozin treatment was found on both Day 1 and 5 using ROI. Conclusions: Short-term canagliflozin treatment may improve cortical oxygenation and lead to better kidney outcomes in patients with T2D.

Indexed as

CanagliflozinDiabetes Mellitus, Type 2KidneyMagnetic Resonance ImagingOxygenSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansHypoglycemic AgentsMaleMiddle AgedCanagliflozinHypoglycemic AgentsOxygenSodium-Glucose Transporter 2 InhibitorsBOLD MRIGFRkidney diseasekidney oxygenationSGLT2 inhibitortype 2 diabetes

Identifiers

PMID39280006
PMCPMC11393780

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.